Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Breast Cancer Congress 2023

HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers

Current ADC landscape

Date

11 May 2023

Session

HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers

Topics

Cytotoxic Therapy;  Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Veronique Dieras

Authors

V.C. Dieras1, H.S. Rugo2

Author affiliations

  • 1 Centre Eugene - Marquis, Rennes/FR
  • 2 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Clinical impact of evolving ADC technology

Presenter: Heather McArthur

Session: HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers

Resources:

Slides

Webcast

Future directions for ADCs

Presenter: Javier Cortes

Session: HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers

Resources:

Slides

Webcast

Q&A and discussion

Presenter: To be Announced

Session: HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.